Select Medical Holdings (SEM) EBITDA Margin (2018 - 2026)

Select Medical Holdings has disclosed EBITDA Margin across 9 years of filings, most recently posting 6.92% for Q1 2026.

• In Q1 2026, EBITDA Margin fell 141.0% year-over-year to 6.92%; the TTM figure through Mar 2026 stood at 5.83% (up 80.0% YoY), while the FY2025 annual figure was 8.71%, up 81.0% from the prior year.
• EBITDA Margin rose to 6.92% in Q1 2026, from 4.58% in the prior quarter.
• Over the last five years, EBITDA Margin for SEM reached as high as 120.13% in Q4 2022 and fell as low as 14.23% in Q4 2023.
• The 5-year median for EBITDA Margin is 6.5% (2022), against an average of 12.63%.
• Annual changes were most pronounced in 2022 — EBITDA Margin jumped 11516 bps — and 2023, when it tumbled 13436 bps.
• A 5-year view of EBITDA Margin shows it stood at 120.13% in 2022, then slumped by 112 bps to 14.23% in 2023, then soared by 111 bps to 1.61% in 2024, then soared by 185 bps to 4.58% in 2025, then soared by 51 bps to 6.92% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 6.92%, 4.58%, and 5.35% for Q1 2026, Q4 2025, and Q3 2025 respectively.